T1	Participants 82 141	middle-and-late stage tumor patients receiving chemotherapy
T2	Participants 326 386	middle-and-late stage tumor patients receiving chemotherapy.
T3	Participants 405 416	60 patients
T4	Participants 50 142	methylation of the MGMT gene in middle-and-late stage tumor patients receiving chemotherapy]
